Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC

Lmcg Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 36,265 shares of the biopharmaceutical company’s stock after purchasing an additional 2,668 shares during the period. Regeneron Pharmaceuticals comprises about 1.2% of Lmcg Investments LLC’s investment portfolio, making the stock its 20th biggest holding. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $20,391,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $38,000. Berbice Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 35 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 1.2%

Shares of REGN stock opened at $733.04 on Friday. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a 50-day simple moving average of $748.87 and a 200 day simple moving average of $636.72. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a market capitalization of $77.04 billion, a P/E ratio of 17.55, a P/E/G ratio of 1.92 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.46 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on REGN. Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. HSBC started coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 target price on the stock. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 8th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $791.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.